Instructions for Tivomax A oral solution 200 mg/ml bottle 100 ml
Composition
active ingredient: L-arginine L-aspartate;
1 ml of solution contains L-arginine L-aspartate 200 mg;
excipients: sorbitol (E 420), methyl parahydroxybenzoate (E 218), propyl parahydroxybenzoate (E 216), sodium saccharin (E 954), caramel flavoring, purified water.
Dosage form
Oral solution.
Main physicochemical properties: slightly yellowish liquid with a caramel odor.
Pharmacotherapeutic group
Other cardiological drugs. Amino acids.
ATX code C01E.
Pharmacological properties
Pharmacodynamics
Tivomax® A has antihypoxic, cytoprotective, antioxidant, detoxification, membrane-stabilizing effects. It plays an important role in the processes of ammonia neutralization and stimulation of its excretion from the body, enhances the detoxification function of the liver. It has a hepatoprotective effect, positively affects the processes of energy supply in hepatocytes.
As a nitric oxide donor, Tivomax® A participates in the processes of energy supply of the body, reduces the activation and adhesion of leukocytes and platelets to the vascular endothelium, preventing the formation and development of atherosclerotic plaques, and is involved in the processes of fibrinogenolysis and spermatogenesis.
The drug has a moderate anabolic effect, stimulates the activity of the thymus gland, promotes insulin synthesis and regulates blood glucose levels during physical exertion, and helps correct acid-base balance.
Pharmacokinetics
Not studied.
Indication
In the complex therapy of ischemic heart disease, atherosclerosis of the heart and brain vessels, arterial hypertension, atherosclerosis of peripheral vessels; diabetic angiopathy; conditions after acute cerebrovascular accident; myocardiopathy, chronic heart failure; hypercholesterolemia; chronic obstructive pulmonary diseases, interstitial pneumonia, idiopathic pulmonary hypertension, chronic postembolic pulmonary hypertension, acute and chronic hepatitis of various etiologies; liver failure, hepatic encephalopathy caused by hyperammonemia; hypoxic and asthenic conditions; immunocorrection in case of decreased thymus function.
Contraindication
Hypersensitivity to the active substance or to any of the excipients of the medicinal product. Severe renal impairment.
Interaction with other medicinal products and other types of interactions
When using arginine aspartate, it should be taken into account that the combined use of aminophylline with arginine may be accompanied by an increase in insulin levels in the blood; spironolactone with arginine - an increase in potassium levels in the blood.
Application features
It should be used with caution in cases of electrolyte imbalance and kidney disease.
The use of the drug in patients who have been diagnosed with myocardial infarction within the previous 6 months is not recommended, as there is a risk of increased post-infarction mortality.
When using the drug, it is necessary to adhere to a balanced sleep and rest regimen, to abandon alcohol, nicotine and psychostimulants. If symptoms of asthenia increase while taking the drug, treatment should be discontinued.
Patients with hereditary fructose intolerance should not take the medicine.
If you have been told you have an intolerance to some sugars, contact your doctor before taking this medicinal product.
Ability to influence reaction speed when driving vehicles or other mechanisms
Does not affect.
Use during pregnancy or breastfeeding
The drug penetrates the placenta, so it can be used during pregnancy only if the expected benefit to the mother outweighs the potential risk to the fetus.
There are no data on the use of the drug during breastfeeding.
Method of administration and doses
Use orally during meals. Adults with ischemic heart disease, atherosclerosis of the heart and brain vessels, atherosclerosis of peripheral vessels, diabetic angiopathy - 5 ml (1 g of the drug) 3-8 times a day. With hypercholesterolemia, conditions after acute cerebrovascular accident, arterial hypertension - 5 ml 3-6 times a day. With chronic obstructive pulmonary diseases, interstitial pneumonia, idiopathic pulmonary hypertension, chronic postembolic pulmonary hypertension - 5 ml 3-6 times a day. Acute and chronic hepatitis of various etiologies, liver failure, hepatic encephalopathy caused by hyperammonemia - 5 ml 3-6 times a day. In hypoxic and asthenic conditions, immunocorrection, with reduced thymus function - 5 ml 4-8 times a day. The maximum daily dose is 8 g. The duration of the course of treatment is 8-15 days; if necessary, the course of treatment is repeated.
Children
Do not use in children under 18 years of age.
Overdose
Treatment. If these symptoms occur, it is necessary to stop taking the drug. Gastric lavage and sorbents are indicated. There is no antidote. Symptomatic therapy.
Adverse reactions
On the part of the gastrointestinal tract: rarely - a feeling of mild discomfort in the stomach and intestines, nausea immediately after taking the drug, which disappear on their own.
Immune system disorders: hypersensitivity reactions, including possible allergic reactions.
The medicine contains excipients such as methyl parahydroxybenzoate, propyl parahydroxybenzoate, which may cause allergic reactions (possibly delayed), and in some cases, bronchospasm.
Expiration date
1.5 years.
The shelf life after opening the bottle is 14 days.
Storage conditions
Store in the original packaging at a temperature not exceeding 25 ° C. Do not freeze.
Keep out of reach of children.
Packaging
100 ml in a bottle; 1 bottle with a measuring spoon or measuring cup in a pack.
Vacation category
Without a prescription
Producer
PrJSC "Pharmaceutical Company "Darnitsa".
Location of the manufacturer and its business address
Ukraine, 02093, Kyiv, Boryspilska St., 13.
